Kobayashi Pharmaceutical Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
735.8K | -0.18% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
462.6K | +0.13% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
351.8K | +6.41% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
174.0K | 0.00% | |
|
MFS Series Trust V-MFS International New Discovery Fund
|
131.5K | +15.35% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Equity ETF
|
117.8K | +0.87% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥104 | +2.0% |
| 2024 | ¥102 | +1.0% |
| 2023 | ¥101 | +12.2% |
| 2022 | ¥90 | +8.4% |
| 2021 | ¥83 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥155,252M | ¥166,258M | ¥173,455M | ¥165,600M |
| Gross Profit | ¥88,773M | ¥92,331M | ¥96,375M | ¥87,603M |
| Operating Income | ¥26,071M | ¥26,674M | ¥25,784M | ¥24,869M |
| Pretax Income | ¥27,654M | ¥27,968M | ¥27,588M | ¥13,942M |
| Net Income | ¥19,715M | ¥20,022M | ¥20,338M | ¥10,067M |
| EPS | ¥252.36 | ¥259.59 | ¥268.16 | ¥135.42 |
| Operating Margin | 16.79% | 16.04% | 14.86% | 15.02% |
| Balance Sheet | ||||
| Total Assets | ¥252,554M | ¥255,827M | ¥267,473M | ¥265,368M |
| Total Equity | ¥195,599M | ¥197,899M | ¥204,816M | ¥213,466M |
| Total Liabilities | ¥56,955M | ¥57,928M | ¥62,657M | ¥51,902M |
| Cash | ¥95,024M | ¥96,233M | ¥71,536M | ¥50,873M |
| Interest-bearing Debt | ¥630M | ¥792M | ¥987M | ¥846M |
| Equity Ratio | 77.45% | 77.36% | 76.57% | 80.44% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥22,419M | ¥31,914M | ¥18,360M | ¥11,246M |
| Investing CF | ¥7,991M | -¥14,312M | -¥19,576M | -¥18,415M |
| Financing CF | -¥10,377M | -¥20,759M | -¥19,463M | -¥7,768M |
| Free CF | ¥18,234M | ¥15,685M | ¥4,791M | -¥15,383M |
| Efficiency | ||||
| ROE | 10.08% | 10.12% | 9.93% | 4.72% |
| ROA | 7.81% | 7.83% | 7.60% | 3.79% |
Latest IR Information
-
Notice Concerning Dividend of Surplus and Withdrawal of Special Reserves
The year-end dividend for the fiscal year ending December 2025 is 60 yen per share, with a total dividend amount of 4,460 million yen. A transfer of 8,300 million yen from special reserves to retained earnings will be made, effective...
Read more -
Notice Regarding Partial Amendment of Articles of Incorporation Due to Transition to a Company with an Audit and Supervisory Committee
Kobayashi Pharmaceutical Co., Ltd. plans to propose amendments to its articles of incorporation at the 108th Annual General Meeting of Shareholders scheduled for March 27, 2026, to transition to a company with an audit and supervisory committee, aiming to strengthen...
Read more -
Notice on Progress of Recurrence Prevention Measures
Kobayashi Pharmaceutical provides a detailed report on the progress of recurrence prevention measures for quality issues related to red yeast rice products, promoting strengthening of a quality and safety-first system and organizational culture reform.
Read more -
Notice Regarding Executive Personnel Changes Following Transition to a Company with an Audit and Supervisory Committee
Subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, the company will transition from a company with a board of auditors to a company with an Audit and Supervisory Committee and has decided on new...
Read more -
Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Kobayashi Pharmaceutical Co., Ltd. will transition from a company with a board of auditors to a company with an audit and supervisory committee, subject to approval at the Annual General Meeting of Shareholders on March 27, 2026, to strengthen its...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥5,501
Rating Score: 2.63 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Kobayashi Pharmaceutical Stock Shocks Japan – What US Investors Must Watch Now - AD HOC NEWS ↗
There May Be Some Bright Spots In Kobayashi Pharmaceutical's (TSE:4967) Earnings - simplywall.st ↗
Company Information
About
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, sanitary and paper products, hand warmers, aloe products, displays, models, mouthpieces, and kaiko; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, and asset management activities. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
